Oral tapentadol for cancer pain

scientific article (publication date: 25 September 2015)

Oral tapentadol for cancer pain is …
instance of (P31):
scholarly articleQ13442814
meta-analysisQ815382

External links are
P356DOI10.1002/14651858.CD011460.PUB2
P8608Fatcat IDrelease_qamjaohtcjesfgibdg6yyv2iju
P932PMC publication ID6483480
P698PubMed publication ID26403220

P50authorSheena DerryQ28036347
Philip J WiffenQ28036553
Rae Jean Proeschold-BellQ90073384
Katrien NaessensQ117285414
P2860cites workTapentadol for chronic musculoskeletal pain in adultsQ24187807
Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer painQ24194524
Impact of covert duplicate publication on meta-analysis: a case studyQ24685600
Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcomeQ26826917
Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effectsQ29619558
The number needed to treat: a clinically useful measure of treatment effectQ29619672
Meta-analysis in clinical researchQ29620885
Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practiceQ33566361
Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended releaseQ33775071
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendationsQ37022616
Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related painQ37352277
The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadolQ38191866
Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related painQ38446521
The pharmacologic management of cancer painQ80238545
Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related painQ87855756
Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related painQ95451268
P433issue9
P921main subjecttapentadolQ414463
cancer painQ3712728
P304page(s)CD011460
P577publication date2015-09-25
P1433published inCochrane Database of Systematic ReviewsQ15750361
P1476titleOral tapentadol for cancer pain

Reverse relations

cites work (P2860)
Q57498749Cancer Pain Management: Opioid Analgesics, Part 2
Q43075660High-dose opioids for chronic non-cancer pain: an overview of Cochrane Reviews.
Q98892340Indian Society for Study of Pain, Cancer Pain Special Interest Group Guidelines on Pharmacological Management of Cancer Pain (Part I)
Q39144886Multidimensional Treatment of Cancer Pain
Q60935032Multiple effectiveness aspects of tapentadol for moderate-severe cancer-pain treatment: an observational prospective study
Q39153206Opioids for cancer pain - an overview of Cochrane reviews.
Q38682609Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults.
Q94333994Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults
Q94333686Oral paracetamol (acetaminophen) for cancer pain
Q38682606Oral paracetamol (acetaminophen) for cancer pain.
Q55023336Spontaneously reported adverse drug events related to tapentadol and oxycodone/naloxone in Australia.
Q24187807Tapentadol for chronic musculoskeletal pain in adults
Q64981989Tapentadol in the management of cancer pain: current evidence and future perspectives.
Q38782574Tramadol with or without paracetamol (acetaminophen) for cancer pain.
Q88271159Understanding osteoporotic pain and its pharmacological treatment
Q50048496Updates in palliative care - overview and recent advancements in the pharmacological management of cancer pain.

Search more.